Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Available 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 3Thoracic 2Sarcoma 2Gynecologic 2Head & Neck 1Dermatologic 1

Conditions

Colorectal Neoplasms 17Pancreatic Neoplasms 6Uterine Cervical Neoplasms 5Rectal Neoplasms 5Colonic Neoplasms 4Stomach Neoplasms 3Prostatic Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Carcinoma, Non-Small-Cell Lung 3Sarcoma 2Ovarian Neoplasms 2Melanoma 2Hemangiosarcoma 2Diabetes Mellitus, Insulin-Dependent, 12 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Resectable MMR-deficient Solid Tumors 1Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Cancer Metastatic 1Oropharyngeal Neoplasms 1Microsatellite Stable Rectal Carcinoma 1Lymphoma 1Gliosarcoma 1Glioma 1Glioblastoma 1Fibrolamellar hepatocellular carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1

Interventions

Docetaxel 292Prednisone 240enzalutamide 193Leuprolide 185Radiotherapy 179Abiraterone Acetate 169Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 92gallium 68 PSMA-11 81abiraterone 81Specimen Handling 73darolutamide 65Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 52Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Prostatic Neoplasms × balstilimab × Clear all
NCT06751524 2026-05-15

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Agenus Inc.

Available
DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Agenus Inc.

Phase 1 Active not recruiting
499 enrolled
GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT06782555 2025-01-21

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

ImmunoGenesis

Phase 1/2 Recruiting
71 enrolled
GastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡